- Previous Close
0.2634 - Open
0.3073 - Bid 0.2634 x --
- Ask 0.3000 x --
- Day's Range
0.2634 - 0.3073 - 52 Week Range
0.0610 - 0.8498 - Volume
7,500 - Avg. Volume
1,632 - Market Cap (intraday)
1.222M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.
www.skinvisible.com2
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SKVI
View MorePerformance Overview: SKVI
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SKVI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SKVI
View MoreValuation Measures
Market Cap
1.22M
Enterprise Value
7.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
56.75
Price/Book (mrq)
--
Enterprise Value/Revenue
371.95
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-197.55%
Return on Equity (ttm)
--
Revenue (ttm)
20k
Net Income Avi to Common (ttm)
-1.18M
Diluted EPS (ttm)
-0.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
612
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
370.79k